Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
received:
08
03
2024
accepted:
30
05
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
2
7
2024
Statut:
aheadofprint
Résumé
Beta-blockers are widely used medications for a variety of indications, including heart failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in pharmacokinetic (e.g., CYP2D6) and pharmacodynamic (e.g., ADRB1, ADRB2, ADRA2C, GRK4, GRK5) genes have been studied in relation to beta-blocker exposure and response. We searched and summarized the strength of the evidence linking beta-blocker exposure and response with the six genes listed above. The level of evidence was high for associations between CYP2D6 genetic variation and both metoprolol exposure and heart rate response. Evidence indicates that CYP2D6 poor metabolizers experience clinically significant greater exposure and lower heart rate in response to metoprolol compared with those who are not poor metabolizers. Therefore, we provide therapeutic recommendations regarding genetically predicted CYP2D6 metabolizer status and metoprolol therapy. However, there was insufficient evidence to make therapeutic recommendations for CYP2D6 and other beta-blockers or for any beta-blocker and the other five genes evaluated (updates at www.cpicpgx.org).
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Institutes of Health (NIH)
ID : R24GM115264
Organisme : National Institutes of Health (NIH)
ID : U24HG010135
Organisme : National Institutes of Health (NIH)
ID : R01HG011800
Organisme : National Institutes of Health (NIH)
ID : K08HL146990
Organisme : National Institutes of Health (NIH)
ID : U24HG010615
Organisme : NIGMS NIH HHS
ID : R35 GM131770
Pays : United States
Organisme : Robert Bosch Stiftung Stuttgart, Germany
ID : P50MD017351
Organisme : Robert Bosch Stiftung Stuttgart, Germany
ID : R01HL132154
Informations de copyright
© 2024 The Author(s). Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Nofziger, C. et al. PharmVar GeneFocus: CYP2D6. Clin. Pharmacol. Ther. 107, 154–170 (2020).
Gaedigk, A., Casey, S.T., Whirl‐Carrillo, M., Miller, N.A. & Klein, T.E. Pharmacogene variation consortium: a global resource and repository for Pharmacogene variation. Clin. Pharmacol. Ther. 110, 542–545 (2021).
CPIC. CPIC® guideline for beta‐blockers and CYP2D6, ADRB1, ADRB2, GRK4, and GRK5. <https://cpicpgx.org/guidelines/cpic‐guideline‐for‐beta‐blockers/> Accessed July 20, 2022.
PharmGKB. Gene‐specific information tables for CYP2D6. <https://www.pharmgkb.org/page/cyp2d6RefMaterials> Accessed July 20, 2022.
Turner, A.J. et al. PharmVar tutorial on CYP2D6 structural variation testing and recommendations on reporting. Clin. Pharmacol. Ther. 114, 1220–1237 (2023).
Rohrer, D.K., Chruscinski, A., Schauble, E.H., Bernstein, D. & Kobilka, B.K. Cardiovascular and metabolic alterations in mice lacking both beta1‐ and beta2‐adrenergic receptors. J. Biol. Chem. 274, 16701–16708 (1999).
Zaccolo, M. cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br. J. Pharmacol. 158, 50–60 (2009).
Ablad, B., Carlsson, B., Carlsson, E., Dahlof, C., Ek, L. & Hultberg, E. Cardiac effects of beta‐adrenergic receptor antagonists. Adv. Cardiol. 12, 290–302 (1974).
Fain, J.N. & Garcija‐Sainz, J.A. Adrenergic regulation of adipocyte metabolism. J. Lipid Res. 24, 945–966 (1983).
Insel, P.A. & Snavely, M.D. Catecholamines and the kidney: receptors and renal function. Annu. Rev. Physiol. 43, 625–636 (1981).
Sandilands, A.J. & O'Shaughnessy, K.M. The functional significance of genetic variation within the beta‐adrenoceptor. Br. J. Clin. Pharmacol. 60, 235–243 (2005).
Bristow, M.R. et al. Decreased catecholamine sensitivity and beta‐adrenergic‐receptor density in failing human hearts. N. Engl. J. Med. 307, 205–211 (1982).
Dishy, V. et al. The effect of common polymorphisms of the beta2‐adrenergic receptor on agonist‐mediated vascular desensitization. N. Engl. J. Med. 345, 1030–1035 (2001).
Green, S.A., Turki, J., Bejarano, P., Hall, I.P. & Liggett, S.B. Influence of beta 2‐adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 13, 25–33 (1995).
Green, S.A., Turki, J., Innis, M. & Liggett, S.B. Amino‐terminal polymorphisms of the human beta 2‐adrenergic receptor impart distinct agonist‐promoted regulatory properties. Biochemistry 33, 9414–9419 (1994).
Hein, L., Altman, J.D. & Kobilka, B.K. Two functionally distinct alpha2‐adrenergic receptors regulate sympathetic neurotransmission. Nature 402, 181–184 (1999).
Small, K.M., Forbes, S.L., Rahman, F.F., Bridges, K.M. & Liggett, S.B. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C‐adrenergic receptor confers impaired coupling to multiple effectors. J. Biol. Chem. 275, 23059–23064 (2000).
Neumeister, A. et al. Sympathoneural and adrenomedullary functional effects of alpha2C‐adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet. Genomics 15, 143–149 (2005).
Kohout, T.A. & Lefkowitz, R.J. Regulation of G protein‐coupled receptor kinases and arrestins during receptor desensitization. Mol. Pharmacol. 63, 9–18 (2003).
Felder, R.A. et al. G protein‐coupled receptor kinase 4 gene variants in human essential hypertension. Proc. Natl. Acad. Sci. USA 99, 3872–3877 (2002).
Premont, R.T., Koch, W.J., Inglese, J. & Lefkowitz, R.J. Identification, purification, and characterization of GRK5, a member of the family of G protein‐coupled receptor kinases. J. Biol. Chem. 269, 6832–6841 (1994).
Liggett, S.B. et al. A GRK5 polymorphism that inhibits beta‐adrenergic receptor signaling is protective in heart failure. Nat. Med. 14, 510–517 (2008).
Caudle, K.E. et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group. Clin. Transl. Sci. 13, 116–124 (2020).
Garcia‐Menaya, J.M., Cordobes‐Duran, C., Garcia‐Martin, E. & Agundez, J.A.G. Pharmacogenetic factors affecting asthma treatment response. Potential implications for drug therapy. Front. Pharmacol. 10, 520 (2019).
Lanfear, D.E. et al. Polygenic score for beta‐blocker survival benefit in European ancestry patients with reduced ejection fraction heart failure. Circ. Heart Fail. 13, e007012 (2020).
Lanfear, D.E. et al. Validation of a polygenic score for Beta‐blocker survival benefit in patients with heart failure using the United Kingdom biobank. Circ. Genom Precis Med. e003835 (2023).
ClinCalc. The top 200 of 2021. <https://clincalc.com/DrugStats/Top200Drugs.aspx> Accessed February 6, 2024.
Blake, C.M., Kharasch, E.D., Schwab, M. & Nagele, P. A meta‐analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin. Pharmacol. Ther. 94, 394–399 (2013).
Lefebvre, J., Poirier, L., Poirier, P., Turgeon, J. & Lacourciere, Y. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br. J. Clin. Pharmacol. 63, 575–582 (2007).
Sehrt, D., Meineke, I., Tzvetkov, M., Gultepe, S. & Brockmoller, J. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 12, 783–795 (2011).
Batty, J.A. et al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT‐HF substudy. Clin. Pharmacol. Ther. 95, 321–330 (2014).
Bijl, M.J. et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta‐blocker users. Clin. Pharmacol. Ther. 85, 45–50 (2009).
Meloche, M., Khazaka, M., Kassem, I., Barhdadi, A., Dube, M.P. & de Denus, S. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: a systematic review and meta‐analysis. Br. J. Clin. Pharmacol. 86, 1015–1033 (2020).
Rau, T. et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin. Pharmacol. Ther. 85, 269–272 (2009).
Thomas, C.D. et al. Examination of metoprolol pharmacokinetics and pharmacodynamics across CYP2D6 genotype‐derived activity scores. CPT Pharmacometrics Syst. Pharmacol. 9, 678–685 (2020).
de Groote, P. et al. Association between beta‐1 and beta‐2 adrenergic receptor gene polymorphisms and the response to beta‐blockade in patients with stable congestive heart failure. Pharmacogenet. Genomics 15, 137–142 (2005).
Metra, M. et al. Role of beta‐adrenergic receptor gene polymorphisms in the long‐term effects of beta‐blockade with carvedilol in patients with chronic heart failure. Cardiovasc. Drugs Ther. 24, 49–60 (2010).
Terra, S.G. et al. Beta1‐adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta‐blocker therapy. Pharmacogenet. Genomics 15, 227–234 (2005).
Rau, T. et al. Impact of the beta1‐adrenoceptor Arg389Gly polymorphism on heart‐rate responses to bisoprolol and carvedilol in heart‐failure patients. Clin. Pharmacol. Ther. 92, 21–28 (2012).
White, H.L. et al. An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study. Eur. J. Heart Fail. 5, 463–468 (2003).
Magnusson, Y. et al. Ser49Gly of beta1‐adrenergic receptor is associated with effective beta‐blocker dose in dilated cardiomyopathy. Clin. Pharmacol. Ther. 78, 221–231 (2005).
Parikh, K.S. et al. Dose response of beta‐blockers in adrenergic receptor polymorphism genotypes. Circ Genom Precis Med 11, e002210 (2018).
Guerra, L.A. et al. Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking beta‐blockers. Pharmacogenomics J. 22, 62–68 (2022).
Cresci, S. et al. Clinical and genetic modifiers of long‐term survival in heart failure. J. Am. Coll. Cardiol. 54, 432–444 (2009).
Sehnert, A.J. et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J. Am. Coll. Cardiol. 52, 644–651 (2008).
Pacanowski, M.A. et al. Beta‐adrenergic receptor gene polymorphisms and beta‐blocker treatment outcomes in hypertension. Clin. Pharmacol. Ther. 84, 715–721 (2008).
U.S. Food and Drug Administration. Table of pharmacogenetic associations. <https://www.fda.gov/medical‐devices/precision‐medicine/table‐pharmacogenetic‐associations#section2> Accessed April 26, 2023.
van Driest, S.L. et al. Variants in ADRB1 and CYP2C9: association with response to atenolol and losartan in Marfan syndrome. J. Pediatr. 222, 213–220 (2020).
Wang, L., Zheng, K., Li, X., Wang, Y. & Xu, Q. Influence of cytochrome P450 2D6 polymorphisms on the efficacy of Oral propranolol in treating infantile hemangioma. Biomed. Res. Int. 2020, 8732871 (2020).
Blake, M.J. et al. Ontogeny of dextromethorphan O‐ and N‐demethylation in the first year of life. Clin. Pharmacol. Ther. 81, 510–516 (2007).
Huddart, R. et al. Standardized biogeographic grouping system for annotating populations in pharmacogenetic research. Clin. Pharmacol. Ther. 105, 1256–1262 (2019).
Aralez Pharmaceuticals US Inc. TOPROL‐XL (metoprolol) [package insert]. U.S. Food and Drug Administration website. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019962s049lbl.pdf> Accessed April 26, 2023.
Cicali, E.J. et al. How to integrate CYP2D6 Phenoconversion into clinical pharmacogenetics: a tutorial. Clin. Pharmacol. Ther. 110, 677–687 (2021).
U.S. Food and Drug Administration. Drug development and drug interactions | Table of substrates, inhibitors and inducers. <https://www.fda.gov/drugs/drug‐interactions‐labeling/drug‐development‐and‐drug‐interactions‐table‐substrates‐inhibitors‐and‐inducers>. Accessed April 26, 2023.
Cicali, E.J., Smith, D.M., Duong, B.Q., Kovar, L.G., Cavallari, L.H. & Johnson, J.A. A scoping review of the evidence behind cytochrome P450 2D6 isoenzyme inhibitor classifications. Clin. Pharmacol. Ther. 108, 116–125 (2020).
Pratt, V.M. et al. Recommendations for clinical CYP2D6 genotyping allele selection: a joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch pharmacogenetics working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy. J. Mol. Diagn. 23, 1047–1064 (2021).